| A802 |
RG-6125
Featured
|
|
|
| A803 |
10C12
Featured
|
|
|
| A804 |
Anti-CDH17/Cadherin-17 Antibody (PTA001_A4)
Featured
|
|
|
| A805 |
PF-03732010
Featured
|
|
|
| A806 |
DS-6000A
Featured
|
|
|
| A807 |
HKT288
Featured
|
|
|
| A808 |
Actoxumab
Featured
|
Actoxumab (Anti-C. difficile Toxin A Recombinant Antibody) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile. Actoxumab has synergy effect with Bezlotoxumab (HY-P9929) targeting TcdB. |
|
| A810 |
Chaim Sheba Med. Cntr. patent anti-CEACAM1
Featured
|
|
|
| A811 |
Tusamitamab
Featured
|
Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize Tusamitamab ravtansine (SAR408701), which is a first-in-class humanized antibody-drug conjugate (ADC) that combines Tusamitamab and DM4 (a potent maytansine derivative). |
|
| A812 |
Labetuzumab
Featured
|
Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy. |
|
| A813 |
Tinurilimab
Featured
|
Tinurilimab (Bay 1834942) is an anti-CEACAM6 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. |
|
| A814 |
NEO-201
Featured
|
|
|
| A815 |
Brown U. patent anti-CHI3L1
Featured
|
|
|
| A816 |
Academia Sinica patent anti-Clathrin Heavy Chain
Featured
|
|
|
| DC67161 |
MPEG-2000-DPPE Na
Featured
|
DPPE-MPEG(2000) is a PEGylated form of 1,2-dipalmitoyl-rac-glycero-3-PE (DPPE). It has been used in the synthesis of anionic liposomes for drug redistribution and toxicity prevention. |
|
| DC67162 |
(S)-GSK-3685032
Featured
|
(S)-GSK-3685032 is the isomer of GSK-3685032 (HY-139664), and can be used as an experimental control. GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1-selective inhibitor, with an IC50 of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibition. |
|
| DC67163 |
1-Piperazinecarboxylic acid, 4-[6-(methoxycarbonyl)-3-pyridinyl]-, 1,1-dimethylethyl ester
Featured
|
|
|
| DC67164 |
WAY-204688
Featured
|
WAY-204688 is an estrogen receptor (ER-α) selective, orally active inhibitor of NF-κB transcriptional activity with an IC50 of 122 ± 30 nM for NF-κB-luciferase (NF-κB-luc) in HAECT-1 cells. |
|
| DC67165 |
Benzamide, 2-[(4-hydroxyphenyl)amino]-4-[4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1H-indazol-1-yl]-
Featured
|
|
|
| DC67166 |
8-((1R,2R)-2-hydroxy-2-methylcyclopentyl)-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
Featured
|
|
|
| DC67167 |
Antifungal agent 35
Featured
|
Antifungal agent 35 (compound 24) is a potent antifungal agent. Antifungal agent 35 is a potent enhancer of antifungal activity of Fluconazole against C. albicans. |
|
| DC67168 |
YAP/TAZ inhibitor-2
Featured
|
YAP/TAZ inhibitor-2 is a potent and orally active TEAD-YAP/TAZ inhibitor with an EC50 value of 3 nM. YAP/TAZ inhibitor-2 shows anti-proliferative activity. YAP/TAZ inhibitor-2 shows antitumor activity. |
|
| DC67169 |
2-Naphthalenecarboxylic acid, 6-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbonyl]-, methyl ester
Featured
|
|
|
| DC67170 |
1-Hydroxy-3,6-bis[2-hydroxy-3-[methyl(phenylmethyl)amino]propoxy]-7-methoxy-2,8-bis(3-methyl-2-buten-1-yl)-9H-xanthen-9-one
Featured
|
|
|
| DC67171 |
Macamide B
Featured
|
Macamide B (N-Benzylhexadecanamide; Macamide 1) is a macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (FAAH). |
|
| DC67172 |
(3R)-Benazepril Hydrochloride
Featured
|
|
|
| DC67173 |
Diacetic Aceclofenac
Featured
|
|
|
| DC67174 |
TK-129
Featured
|
TK-129 is an orally active, low-toxicity, potent KDM5B inhibitor (with high affinity; IC50=44 nM). TK-129 exerts cardioprotective effects by inhibiting KDM5B and blocking the KDM5B-associated Wnt pathway. TK-129 reduces ang II-induced activation of cardiac fibroblasts in vitro and reduces isoprenaline-induced myocardial remodelling and fibrosis in vivo. TK-129 can be used in studies of cardiovascular disease. |
|
| DC67175 |
ATX968
Featured
|
ATX968 (example 31) is an inhibitor of ATP-dependent RNA helicase A (DHX9), with the EC50 of 0.054 μM in circBRIP1. ATX968 has antitumor activity. |
|
| DC67176 |
N-(2-methylpropyl)decanamide
Featured
|
|
|
